BTN2A1 and ovarian cancer: Together, αβ and γδ T cells elicited superior control of established ovarian cancer xenografts in response to these BTN3A1 antibodies, in a manner that was superior to PD-1 checkpoint therapy and dependent on the expression of a second butyrophilin (BTN2A1) [3].